DOI QR코드

DOI QR Code

Plasma Soluble CD30 as a Possible Marker of Adult T-cell Leukemia in HTLV-1 Carriers: a Nested Case-Control Study

  • Takemoto, Shigeki (Clinical Laboratory, National Hospital Organization Kumamoto Medical Center, Graduate School of Medical Sciences Kumamoto University) ;
  • Iwanaga, Masako (Department of Frontier Life Science, Nagasaki University Graduate School of Biomedical Sciences) ;
  • Sagara, Yasuko (Department of Quality, Japanese Red Cross Kyushu Block Blood Center) ;
  • Watanabe, Toshiki (Department of Medical Genome Science, Graduate School of Frontier Sciences, University of Tokyo)
  • Published : 2016.01.11

Abstract

Elevated levels of soluble CD30 (sCD30) are linked with various T-cell neoplasms. However, the relationship between sCD30 levels and the development of adult T-cell leukemia (ATL) in human T-cell leukemia virus type 1 (HTLV-1) carriers remains to be clarified. We here investigated whether plasma sCD30 is associated with risk of ATL in a nested case-control study within a cohort of HTLV-1 carriers. We compared sCD30 levels between 11 cases (i.e., HTLV-1 carriers who later progressed to ATL) and 22 age-, sex- and institution-matched control HTLV-1 carriers (i.e., those with no progression). The sCD30 concentration at baseline was significantly higher in cases than in controls (median 65.8, range 27.2-134.5 U/mL vs. median 22.2, range 8.4-63.1 U/mL, P=0.001). In the univariate logistic regression analysis, a higher sCD30 (${\geq}30.2U/mL$) was significantly associated with ATL development (odds ratio 7.88 and the 95% confidence intervals 1.35-45.8, P = 0.02). Among cases, sCD30 concentration tended to increase at the time of diagnosis of aggressive-type ATL, but the concentration was stable in those developing the smoldering-type. This suggests that sCD30 may serve as a predictive marker for the onset of aggressive-type ATL in HTLV-1 carriers.

Keywords

Adult T-cell leukemia (ATL);CD30;human T-cell leukemia virus type 1 (HTLV-1)

References

  1. Anagnostopoulos I, Hummel M, Kaudewitz P, et al (1990). Detection of HTLV-I proviral sequences in CD30-positive large cell cutaneous T-cell lymphomas. Am J Pathol, 137, 1317-22.
  2. Breen EC, Fatahi S, Epeldegui M, et al (2006). Elevated serum soluble CD30 precedes the development of AIDS-associated non-Hodgkin's B cell lymphoma. Tumour Biol, 27, 187-94. https://doi.org/10.1159/000093022
  3. Caligaris-Cappio F, Bertero MT, Converso M, et al (1995). Circulating levels of soluble CD30, a marker of cells producing Th2-type cytokines, are increased in patients with systemic lupus erythematosus and correlate with disease activity. Clin Exp Rheumatol, 13, 339-43.
  4. Franchini G (1995). Molecular mechanisms of human T-cell leukemia/lymphotropic virus type I infection. Blood, 86, 3619-39.
  5. Gause A, Pohl C, Tschiersch A, et al (1991). Clinical significance of soluble CD30 antigen in the sera of patients with untreated Hodgkin's disease. Blood, 77, 1983-8.
  6. Gerli R, Muscat C, Bistoni O, et al (1995). High levels of the soluble form of CD30 molecule in rheumatoid arthritis (RA) are expression of CD30+ T cell involvement in the inflamed joints. Clin Exp Immunol, 102, 547-50.
  7. Giacomelli R, Cirripani P, Lattazio R, et al (1997). Circulating levels of soluble CD30 are increased in patients with systemic sclerosis (SSc) and correlate with serological and clinical features of disease. Clin Exp Immunol, 108, 42-6. https://doi.org/10.1046/j.1365-2249.1997.d01-991.x
  8. Higuchi M, Matsuda T, Mori N, et al (2005). Elevated expression of CD30 in adult T-cell leukemia cell lines: possible role in constitutive NF-kappaB activation. Retrovirol, 2, 29. https://doi.org/10.1186/1742-4690-2-29
  9. Horie R, Watanabe T (1998). CD30: expression and function in health and disease. Semin Immunol, 10, 457-70. https://doi.org/10.1006/smim.1998.0156
  10. Iwanaga M, Watanabe T, Utsunomiya A, et al (2010). Human T-cell leukemia virus type I (HTLV-1) proviral load and disease progression in asymptomatic HTLV-1 carriers: a nationwide prospective study in Japan. Blood, 116, 1211-9. https://doi.org/10.1182/blood-2009-12-257410
  11. Krams SM, Cao S, Hayashi M, Villanueva JC, Martinez OM (1996). Elevations in IFN-${\gamma}$, IL-5, and IL-10 in patients with the autoimmune primary biliary cirrhosis: association with autoantibodies and soluble CD30. Clin Immunol Immonopathol, 80, 311-20. https://doi.org/10.1006/clin.1996.0129
  12. Michai M, Goto H, Hattori S, et al (2012). Soluble CD30: a possible serum tumor marker for primary effusion lymphoma. Asian Pac J Cancer Prev, 13, 4939-41. https://doi.org/10.7314/APJCP.2012.13.10.4939
  13. Muta H, Podack ER (2013). CD30: from basic research to cancer therapy. Immunol Res, 57, 151-8. https://doi.org/10.1007/s12026-013-8464-1
  14. Nakada K, Kohakura M, Komoda H, Hinuma Y (1984). High incidence of HTLV antibody in carriers of Strongyloides stercoralis. Lancet, 1, 633.
  15. Nishioka C, Takemoto S, Kataoka S, et al (2005). Serum level of soluble CD30 correlates with the aggressiveness of adult T-cell leukemia/lymphoma. Cancer Sci, 96, 810-5. https://doi.org/10.1111/j.1349-7006.2005.00106.x
  16. Ohtsuka E, Kikuchi H, Nasu M, et al (1994). Clinicopathological features of adult T-cell leukemia with CD30 antigen expression. Leuk Lymphoma, 15, 303-10. https://doi.org/10.3109/10428199409049728
  17. Okamoto T, Ohno Y, Tsugane S, et al (1989). Multi-step carcinogenesis model for adult T-cell leukemia. Jpn J Cancer Res; 80: 191-195. https://doi.org/10.1111/j.1349-7006.1989.tb02289.x
  18. Pfreundschuh M, Pohl C, Berenbeck C, et al (1990). Detection of a soluble form of the CD30 antigen in sera of patients with lymphoma, adult T-cell leukemia and infectious mononucleosis. Int J Cancer, 45, 869-74. https://doi.org/10.1002/ijc.2910450515
  19. Pornkuna R, Takemoto S, Hidaka M, Kawano F, Haga Y (2014a). Clinical value of serum soluble CD30 levels in adult T-cell leukemia/lymphoma. J Hematol Thrombo Dis, 2, 167.
  20. Pornkuna R, Nishioka C, Takemoto S (2014b). What is the role of soluble cytokine receptors in adult T-cell leukemia/ lymphoma? J Hematol Thrombo Dis, 2, 154.
  21. Purdue MP, Lan Q, Martinez-Maza O, et al (2009). A prospective study of serum soluble CD30 concentration and risk of non-Hodgkin lymphoma. Blood, 114, 2730-2. https://doi.org/10.1182/blood-2009-04-217521
  22. Shimoyama M (1991). Diagnostic criteria and classification of clinical subtypes of adult T-cell leukemia-lymphoma. Br J Haematol, 79, 428-37. https://doi.org/10.1111/j.1365-2141.1991.tb08051.x
  23. Takatsuki K, Yamaguchi K, Kawano F, et al (1985). Clinical diversity in adult T-cell leukemia-lymphoma. Cancer Res, 45, 4644-5.
  24. Takemoto S, Matsuoka M, Yamaguchi K, Takatsuki K (1994). A novel diagnostic method of adult T-cell leukemia: Monoclonal integration of human T-cell lymphotropic virus type I proviral DNA detected by inverse polymerase chain reaction. Blood, 84, 3080-5.
  25. Takemoto S, Morimatsu Y, Pornkuna R, Murayama T, Kawano F (2014). CD30+ cells in lung of indolent type adult T-cell leukemia/lymphoma and elevated serum levels of soluble CD30 associated with acute crisis and relapse of disease. J Leuk, 2, 166.
  26. Takeshita M, Akamatsu M, Ohshima K, et al (1995). CD30 (Ki-1) expression in adult T-cell leukaemia/lymphoma is associated with distinctive immunohistological and clinical characteristics. Histopathol, 26, 539-46. https://doi.org/10.1111/j.1365-2559.1995.tb00272.x
  27. Tang C, Yamada H, Shibata K, et al (2008). A novel role of CD30L/CD30 signaling by T-T cell interaction in Th1 response against mycobacterial infection. J Immunol, 181, 6316-27. https://doi.org/10.4049/jimmunol.181.9.6316
  28. Trinchieri G (2012). Cancer and inflammation: an old intuition with rapidly evolving new concepts. Annu Rev Immunol, 30, 677-706. https://doi.org/10.1146/annurev-immunol-020711-075008
  29. Tsukasaki K, Tsushima H, Yamamura M, et al (1997). Integration patterns of HTLV-I proviral in relation to the clinical course of ATL: frequent clonal change at crisis from indolent disease. Blood, 89, 948-56.
  30. Uchiyama T, Yodoi J, Segawa K, Uchino H (1977). Adult T-cell leukemia: Clinical and hematologic features of 16 cases. Blood, 50, 481-92.
  31. Yamaguchi K (1994). Human T-lymphotropic virus type I in Japan. Lancet, 343, 213-6. https://doi.org/10.1016/S0140-6736(94)90994-6
  32. Yoshida M, Miyoshi I, Hinuma Y (1982). Isolation and characterization of retrovirus from cell lines of human adult T-cell leukemia and its implication in the disease. PNAS, 79, 2031-5. https://doi.org/10.1073/pnas.79.6.2031
  33. Zhao T, Matsuoka M (2012). HBZ and its roles in HTLV-1 oncogenesis. Front Microbiol, 3, 247.

Cited by

  1. Human T-cell lymphotropic virus type 1 and its oncogenesis vol.38, pp.8, 2017, https://doi.org/10.1038/aps.2017.17
  2. A practical cytological approach to the diagnosis of breast-implant associated anaplastic large cell lymphoma pp.09565507, 2019, https://doi.org/10.1111/cyt.12678